IVVD
$1.59
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States.
Intraday
Recent News
Invivyd Q4 Earnings Call Highlights
Invivyd (NASDAQ:IVVD) executives used the company’s fourth-quarter 2025 earnings call to outline progress in its COVID-19 monoclonal antibody pipeline, provide an update on commercialization of PEMGARDA, and review recent financial results and liquidity. Leadership update and strategic focus Chairm
Invivyd Inc (IVVD) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Invivyd Inc (IVVD) reports a 31% increase in PEMGARDA net revenues and strategic advancements, positioning itself for future growth despite market challenges.
Invivyd, Inc. Q4 2025 Earnings Call Summary
Moby summary of Invivyd, Inc.'s Q4 2025 earnings call
MannKind (MNKD) Reports Q4 Loss, Tops Revenue Estimates
MannKind (MNKD) delivered earnings and revenue surprises of -900.00% and +15.68%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Halozyme Therapeutics (HALO) Reports Q4 Loss, Tops Revenue Estimates
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of -111.16% and +0.70%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?